July 1, 2016 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Currently FDA provides an array of expedited programs and designations for specialty drugs and biologics intended to facilitate and expedite development and review of new specialty drugs to address unmet medical need in the treatment of a serious or life threatening […]
June 30, 2016 - Atlanta, Georgia - The Atlanta Chapter of the Association for Corporate Growth® (ACG), a global professional organization with the mission of Driving Middle-Market Growth®, ranks Curant Health as #9 of the top 40 fastest-growing upper middle-market companies in Georgia. This year also marks Curant Health as a four time recipient of […]
Value-based contracts between pharmaceutical manufacturers and payers are a fast-growing, new development that is here to stay. These pharma contracts put in place a reward system - higher payment rates - in exchange for demonstrably improved patient outcomes. This type of agreement is intended to reward healthcare value over volume. Some outcomes can be measured […]
As medical cures advance, the umbrella covering chronic conditions does, too. Increasingly, the future of cancer treatment, with increased numbers of immunotherapies and oral oncolytics, will begin to emulate treatments for chronic illnesses. Along with this progress come big questions, like when, if ever will it be safe for a cancer patient to stop treatment? […]
June 2, 2016 - Curant Health COO, Marc O'Connor, in Specialty Pharmacy Times - Signs point to cancer becoming a chronic condition in the near future. According to a study by Wei Zheng, MD, PhD, and others, published in the Journal of the American Medical Association as reported by Reuters in 2015, “For men and […]
June 1, 2016 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Value-based contracts between pharmaceutical manufacturers and payers look like they are here to stay. And they are growing in number. The Wall Street Journal reported last month that payers and PBMs have reached at least a dozen “value-based” or “at-risk” deals […]
May 21, 2016 - Curant COO, Marc O'Connor, in Managed Healthcare Executive - Advancements in cancer care and therapies indicate it is on track to become a chronic condition. According to a study published in the Journal of the American Medical Association, “For men and women ages 50 to 64, who were diagnosed in 2005 […]
This year the Asembia Specialty Pharmacy Summit, previously known as the Armada Specialty Pharmacy Summit, left us with some key learnings. Here are four of my takeaways from Armada, nay, Asembia 2016: The absence of the PBMs was noticeable and curious. There were two PBMs with noticeably sparse attendance at this year’s gathering - Express […]
May 13, 2016 - Curant COO, Marc O'Connor, in Managed Healthcare Executive - Late spring signals the top conference in specialty pharmacy every year, the Asembia Specialty Pharmacy Summit, previously known as the Armada Specialty Pharmacy Summit. 1. The absence of the PBMs was noticeable and curious. Typically Express Scripts and Aetna have a presence at the […]
What we’ve learned from the introduction of high-cost hepatitis C drugs should be used for effective stakeholder alignment and the rollout of future curative therapies: The development of Sovaldi, Harvoni and other leading-edge therapies for hepatitis C was driven in large part by payer and patient demands for drugs with proven cure rates. Manufacturers responded […]
